<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Communidade:</title>
  <link rel="alternate" href="http://repositorio.ufc.br/handle/riufc/59153" />
  <subtitle />
  <id>http://repositorio.ufc.br/handle/riufc/59153</id>
  <updated>2026-06-18T16:49:21Z</updated>
  <dc:date>2026-06-18T16:49:21Z</dc:date>
  <entry>
    <title>Avaliação do potencial tripanocida in vitro da curcumina e de sua associação com o benznidazol frente à cepa y de Trypanosoma cruzi</title>
    <link rel="alternate" href="http://repositorio.ufc.br/handle/riufc/86802" />
    <author>
      <name>Abreu, Karina Gatti de</name>
    </author>
    <id>http://repositorio.ufc.br/handle/riufc/86802</id>
    <updated>2026-06-17T16:27:45Z</updated>
    <published>2025-01-01T00:00:00Z</published>
    <summary type="text">Título: Avaliação do potencial tripanocida in vitro da curcumina e de sua associação com o benznidazol frente à cepa y de Trypanosoma cruzi
Autor(es): Abreu, Karina Gatti de
Abstract: Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is an infectious disease that&#xD;
requires new treatments approaches to mitigate its progression. Curcumin, the main active&#xD;
compound of Curcuma longa L., has been investigated for its therapeutic potential in parasitic&#xD;
diseases. Therefore, the present study evaluated the in vitro trypanocidal activity of isolated&#xD;
curcumin and its combination with benznidazole (BZN) against the Y strain of T. Cruzi, as well&#xD;
as analyzed in silico its action on essential metabolic pathways of the parasite. The cytotoxicity&#xD;
of curcumin and BZN was tested in LLC-MK2 cells, with 50% cytotoxic concentration (CC50)&#xD;
values of 178.2 ± 0.27 μM and 537.8 ± 57.8 μM, respectively. Curcumin exhibited significant&#xD;
inhibitory activity at all parasite stages: epimastigotes (IC50/72 h of 34.45 ± 4.73 μM),&#xD;
trypomastigotes (LC50 of 72.36 ± 2.057 μM), and amastigotes (reduction in infected cells at&#xD;
31.25 μM and 62.5 μM). BZN alone also showed an inhibitory effect, but at higher&#xD;
concentrations than those observed with isolated curcumin. The Curcumin-BZN combination&#xD;
demonstrated synergy, with high selectivity against the parasite and low cytotoxicity in host&#xD;
cells. The combined effect of Curcumin and BZN resulted in a significant reduction in cell&#xD;
viability in epimastigote and trypomastigote forms. Furthermore, the combination exhibited&#xD;
greater selectivity toward the parasite compared to the isolated compounds. Molecular docking&#xD;
analyses identified curcumin binding sites in key parasite enzymes, such as trypanothione&#xD;
reductase, glyceraldehyde 3-phosphate dehydrogenase (TcGAPDH), and cruzipain, suggesting&#xD;
potential inhibitory effects and/or conformational changes in enzyme structure. Thus, it is&#xD;
concluded that curcumin, either alone or in combination with BZN, emerges as promising&#xD;
candidate for the treatment of CD, standing out for its efficacy and selectivity against T. cruzi.
Tipo: Dissertação</summary>
    <dc:date>2025-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Exposição pré-natal ao SARS-CoV-2, ativação imune materno-fetal e desfechos do neurodesenvolvimento infantil</title>
    <link rel="alternate" href="http://repositorio.ufc.br/handle/riufc/86557" />
    <author>
      <name>Kehdi, Renata Castro</name>
    </author>
    <id>http://repositorio.ufc.br/handle/riufc/86557</id>
    <updated>2026-06-01T17:13:39Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Título: Exposição pré-natal ao SARS-CoV-2, ativação imune materno-fetal e desfechos do neurodesenvolvimento infantil
Autor(es): Kehdi, Renata Castro
Abstract: This thesis investigates the relationship between maternal SARS-CoV-2 infection and the&#xD;
expression of pro-inflammatory markers in children up to 18 months of age. The research&#xD;
bases itself on the theory that the activation of the maternal immune system during pregnancy&#xD;
(MIA), due to exposure to pathogens such as SARS-CoV-2, can lead to the release of&#xD;
pro-inflammatory cytokines that remodel fetal brain connections, increasing the risk of&#xD;
neurodevelopmental disorders. In terms of methodology, the investigation uses the&#xD;
PLACOVGEN-BR cohort from the Neuropsychopharmacology Laboratory&#xD;
(LABNEURO/NPDM/UFC) in collaboration with the Assis Chateaubriand School Maternity&#xD;
(MEAC/UFC) and the Nucleus for Early Treatment and Stimulation (NUTEP), collecting data&#xD;
from pregnant women and their children between 2021 and 2023, involving the measurement&#xD;
of cytokines and chemokines in biospecimens via multiplex assay and the clinical evaluation&#xD;
of offspring neurodevelopment using gold-standard scales, such as the Bayley scale, to&#xD;
analyze cognitive, motor, and communication domains. The findings showed that prenatal&#xD;
exposure to SARS-CoV-2 was associated with a high frequency of neurodevelopmental&#xD;
delays at 24 months, particularly in the communication and motor domains. An increasing&#xD;
frequency of delays was observed between 6 and 24 months, especially in communication.&#xD;
Additionally, elevated levels of cytokines and chemokines in umbilical cord blood were&#xD;
associated with the observed outcomes, suggesting that perinatal inflammatory mediators,&#xD;
such as IFN-γ, TNF-α, IL-6, IL-8, IL-17, IL-1β, and CXCL10, may serve as early risk&#xD;
biomarkers for neurodevelopmental alterations in children exposed in utero to SARS-CoV-2.&#xD;
Taken together, these findings indicate that prenatal exposure to SARS-CoV-2 may adversely&#xD;
affect infant neurodevelopment, possibly through mechanisms involving maternal-fetal&#xD;
immune activation. These results reinforce the importance of longitudinal follow-up of&#xD;
children exposed during pregnancy and suggest the potential of perinatal inflammatory&#xD;
biomarkers for early risk identification.
Tipo: Tese</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Caracterização genética da Neoplasia Endócrina Múltipla do Tipo 1 no Baixo Jaguaribe, Ce: o impacto do rastreamento molecular da variante germinativa, MEN1 c.654G&gt;T</title>
    <link rel="alternate" href="http://repositorio.ufc.br/handle/riufc/86540" />
    <author>
      <name>Pinheiro, Sabrina Magalhães Pedrosa Rocha</name>
    </author>
    <id>http://repositorio.ufc.br/handle/riufc/86540</id>
    <updated>2026-05-30T11:57:47Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Título: Caracterização genética da Neoplasia Endócrina Múltipla do Tipo 1 no Baixo Jaguaribe, Ce: o impacto do rastreamento molecular da variante germinativa, MEN1 c.654G&gt;T
Autor(es): Pinheiro, Sabrina Magalhães Pedrosa Rocha
Abstract: Multiple Endocrine Neoplasia type 1 (MEN1) is a rare autosomal dominant inherited&#xD;
syndrome caused by pathogenic germline variants in the MEN1 gene, predisposing&#xD;
affected individuals to the development of endocrine and non-endocrine neoplasms,&#xD;
most commonly involving the parathyroid glands, pituitary gland, and&#xD;
duodenopancreatic endocrine cells. The clinical diagnosis of MEN1 is established&#xD;
when at least one of the following criteria is met: the presence of tumours affecting at&#xD;
least two MEN1-associated endocrine tissues; the occurrence of a single MEN1-&#xD;
associated tumour in a first-degree relative of an individual with a confirmed clinical&#xD;
diagnosis; or the identification of a pathogenic germline variant in the MEN1 gene.&#xD;
This study defined a geographical microregion in Baixo Jaguaribe, in the interior of&#xD;
Ceará, Brazil, to investigate the clinical variability of MEN1 cases in carriers of the&#xD;
pathogenic germline variant NM_001370259.2(MEN1):654+1G&gt;T and to assess the&#xD;
impact of implementing molecular screening for this variant among at-risk relatives&#xD;
residing in the region. A care pathway was proposed, offering Sanger sequencing to&#xD;
patients with a clinical diagnosis and their at-risk relatives, in addition to the&#xD;
construction of pedigree charts for family investigation. The study included 50&#xD;
individuals: five index cases with a confirmed clinical diagnosis and 45 relatives, all&#xD;
belonging to five families from the same geographical region, with no known parental&#xD;
relationship between the families. The index cases were genetically confirmed through&#xD;
identification of the pathogenic MEN1 variant. Among the 45 at-risk relatives, 18&#xD;
(40.0%) had inherited the variant, whereas 27 (60.0%) did not carry it and were&#xD;
therefore excluded from clinical follow-up. Of the total number of variant carriers, ten&#xD;
were asymptomatic (43.5%). In the study cohort, the 23 individuals carrying the variant&#xD;
were divided into three groups: index cases (n = 5), with a mean age of 45.6 years&#xD;
(±15.2); relatives with clinical manifestations (n = 8), with a mean age of 48.1 years&#xD;
(±14.3); and asymptomatic family members (n = 10), with a mean age of 27.8 years&#xD;
(±13.9). Age analysis revealed a significant difference between symptomatic and&#xD;
asymptomatic family members (p = 0.027), suggesting that early access to genetic&#xD;
testing in this at-risk population may improve prognosis and reduce morbidity and&#xD;
mortality. Furthermore, the mean ages of the index cases and symptomatic relatives&#xD;
suggest a prolonged interval between symptom onset and referral to specialized care,&#xD;
delaying family screening, whereas the younger age of asymptomatic individuals&#xD;
underscores the importance of early diagnosis. No significant differences were&#xD;
observed between sexes. Regarding clinical manifestations, pituitary tumours were&#xD;
prevalent among index cases, with the classic MEN1 triad present in four of the five&#xD;
individuals. Among symptomatic relatives, primary hyperparathyroidism and&#xD;
gastroenteropancreatic neuroendocrine tumours were the most frequent initial&#xD;
manifestations. Skin lesions suggestive of collagenomas were identified in three&#xD;
individuals and may represent important clinical warning signs. The study involved&#xD;
active and systematic screening, including pedigree construction and genetic&#xD;
sequencing across multiple generations of five families, revealing a pattern of vertical&#xD;
transmission consistent with highly penetrant autosomal dominant inheritance. The&#xD;
identification of the same pathogenic variant in unrelated index cases, in a region&#xD;
without previously described MEN1 mutational hot spots, suggests a possible founder&#xD;
effect, potentially associated with geographical isolation and/or inbreeding&#xD;
characteristic of rural communities.
Tipo: Tese</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Inovação, evidências e aplicações clínicas da pele de tilápia (Oreochromis niloticus) na medicina veterinária: uma revisão de escopo</title>
    <link rel="alternate" href="http://repositorio.ufc.br/handle/riufc/86405" />
    <author>
      <name>Araripe, Lídia Sampaio Batista De Alencar</name>
    </author>
    <id>http://repositorio.ufc.br/handle/riufc/86405</id>
    <updated>2026-05-21T12:16:56Z</updated>
    <published>2026-01-01T00:00:00Z</published>
    <summary type="text">Título: Inovação, evidências e aplicações clínicas da pele de tilápia (Oreochromis niloticus) na medicina veterinária: uma revisão de escopo
Autor(es): Araripe, Lídia Sampaio Batista De Alencar
Abstract: Nile tilapia (Oreochromis niloticus) skin is an innovative biomaterial in regenerative&#xD;
medicine due to its high type I collagen content, biocompatibility, and low cost. This thesis&#xD;
presents a scoping review conducted to map and synthesize scientific evidence on the&#xD;
clinical use of tilapia skin and its derivatives in veterinary medicine. The methodology&#xD;
followed the PRISMA-ScR guidelines and the Joanna Briggs Institute (JBI)&#xD;
&#xD;
recommendations, utilizing PubMed, Scopus, and Google Scholar databases. Twenty-&#xD;
nine studies published between 2015 and 2026 were included, encompassing original&#xD;
&#xD;
articles, case reports, and grey literature. The results demonstrate that Brazil leads&#xD;
scientific production in the field (approximately 65.5% of the studies). The main&#xD;
applications identified focus on two primary axes: cutaneous wounds (of various&#xD;
etiologies) and ophthalmology. Applications occurred in several species, such as dogs,&#xD;
cats, horses, donkeys, and wild animals. The biomaterial was used in various processing&#xD;
forms, including in natura, glycerol-preserved, lyophilized, and acellular dermal matrices.&#xD;
The evidence suggests that the use of tilapia skin as a xenograft promotes accelerated&#xD;
re-epithelialization, pain reduction, protection against contamination, and a decreased&#xD;
frequency of dressing changes, resulting in improved patient comfort and cost reduction.&#xD;
It is concluded that although the use of tilapia skin has shown excellent results in various&#xD;
applications and species without reports of adverse effects, there is still methodological&#xD;
heterogeneity and a predominance of case reports and experimental studies with small&#xD;
sample sizes. This highlights the need for further research involving standardized clinical&#xD;
trials and more robust cohorts to consolidate protocols in veterinary medicine.
Tipo: Tese</summary>
    <dc:date>2026-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

